Please login to the form below
Glythera strengthens its scientific advisory board and appoints CSO
Dr Robert Lutz and Dr Jon Roffey join the UK biotech
Glythera has appointed new chief scientific officer Dr Robert Lutz to lead the advancement of the UK-based biotech's antibody drug conjugate portfolio.
Dr Lutz was previously vice president of translation research and development at ImmunoGen, where he was responsible for all early-stage ADC development programmes.
Additionally, Dr Jon Roffey joins Glythera’s scientific advisory board (SAB) from Cancer Research Technology (CRT), Cancer Research UK’s commercial partnerships team, where he had been working since 2006.
Dr Dave Simpson, chief executive officer of Glythera, said: “Robert Lutz’s experience in ADC development will be a great asset as Glythera continued to develop our pipeline of cancer treatments.
“With his appointment as CSO, and the addition of Jon to our SAD, we start 2018 in a strengthened position as developers of the very best novel agents and targeted treatments, aiming to improve the lives of patients living with cancers that are the hardest to treat.”
COVID-19 Updates and Daily News
Featured jobs
-
Head of Copy
-
£ competitive
- Pfizer CEO announces plans to launch Omicron-specific COVID-19 vaccine
- Sanofi and Exscientia agree on a deal worth up to $5.2bn for AI-driven therapies
- Biogen’s Alzheimer’s treatment Aduhelm limited to clinical trial participants in the US
- Pfizer expands access to lipid nanoparticle technology in new agreement with Acuitas Therapeutics
- BioNTech and InstaDeep collaboration develops SARS-CoV-2 Early Warning System
- BMS and Century Therapeutics agree on deal potentially worth over $3bn
- Live Webinar: Measuring Vital Health Indicators Through Your Camera
- AstraZeneca's Enhertu receives FDA grant for priority review
- Pfizer’s Cibinqo granted FDA approval for adults with moderate-to-severe atopic dermatitis
- Julie Beeso joins Envision Pharma Group in new Global Director, Professional Development and Engagement role
- Live Webinar: Expanding Access to High-Quality Healthcare
- Vir Biotech launches new research programme for HIV and malaria prevention
- Sanofi and Exscientia agree on a deal worth up to $5.2bn for AI-driven therapies
- Why pharma must get smart in its approach to customer engagement
- NAVIGATING 2022: THE FIVE CRITICAL SHIFTS PHARMA NEEDS TO EMBRACE
- Amgen’s Lumykras receives conditional marketing authorisation from EC
- BMS and Century Therapeutics agree on deal potentially worth over $3bn
- FDA nod for Janssen schizophrenia treatment Invega Hafyera
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
Latest intelligence
- The doctor will text you now: Why healthcare providers cannot underestimate the importance of communicating change
- Healthcare communication needs to switch from ‘transmit’ to ‘receive’, listening to what patients need and embracing the plethora of communication tools wholeheartedly....
- How to innovate and influence people in times of misinformation
- The pandemic has shown that public trust in promising new medical technologies is far from a given. Senior Writer Tom Vandyck at StoneArch, a member of Fishawack delves into the...
- Could femtech be the answer to the gender health gap?
- Here, we discuss the phenomenon of femtech, an industry that puts women’s experiences of lifestyle and health front and centre. We highlight some of the major players in the industry,...
